ArticleCell death discovery2025
Circular RNA profiling identifies circ_0001522, circ_0001278, and circ_0001801 as predictors of unfavorable prognosis and drivers of triple-negative breast cancer hallmarks.
Article in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- CircRNAs in hepatic lipid metabolism: regulatory mechanisms and clinical implications.Frontiers in genetics · 2026Review
- Circular RNAs in Plasma and Beyond: Potential Biomarkers for Breast Cancer.Oncology research · 2026Review
- Circ72688 Drives Breast Cancer Invasion and Metastasis via the miR-654-5p/ORAI2 Axis.Oncology research · 2026Article
- Circular RNAs orchestrating breast cancer hallmarks: bridging tumor biology and therapy resistance.Functional & integrative genomics · 2025Review
- Exploring the Clinical Transformation of circRNA as a Biomarker in Breast Cancer.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer poses a significant clinical challenge due to its complex molecular landscape, underscoring the need for improved prognostic and therapeutic strategies. In this study, we explored the expression profiles and therapeutic relevance of circular RNAs (circRNAs) in a cohort of 96 breast cancer patients from Qatar representing the MENA region. Our data identified distinct expression patterns in relation to breast cancer subtypes, tumor grade, and age, with fifty circRNAs found to be associated with unfavorable relapse-free survival (RFS). The expression of sixteen of these circRNAs was validated in triple-negative breast cancer (TNBC) model using RNase R resistance assay. Among these, the expression of circ_0001522, circ_0001278, and circ_0001801 was validated using divergent primers, and their backsplice junctions were confirmed using Sanger sequencing. Functionally, siRNA-mediated knockdown of these circRNAs significantly suppressed cell proliferation, colony formation, three-dimensional organoid growth, and cell migration in TNBC models. Mechanistic investigations revealed that circRNA depletion altered a subset of miRNA and mRNA expressions, with key interactions involving miR-4458, miR-145-5p, and miR-760, regulating critical targets such as CCND1, ROBO4, and MMP1. Additionally, circRNA-RBP bioinformatic analysis identified common binding partners, including AGO2, CPSF7, TARDBP, UPF1, and LIN28B, suggesting roles in post-transcriptional regulation. Our data highlight circ_0001522, circ_0001278, and circ_0001801 as promising prognostic and therapeutic circRNA targets for breast cancer, offering new avenues for improving breast cancer prognosis and treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.